258 related articles for article (PubMed ID: 15205349)
21. Protection of CCRF-CEM human lymphoid cells from antifolates by retroviral gene transfer of variants of murine dihydrofolate reductase.
Mareya SM; Sorrentino BP; Blakley RL
Cancer Gene Ther; 1998; 5(4):225-35. PubMed ID: 9694074
[TBL] [Abstract][Full Text] [Related]
22. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
23. p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.
Hopkins-Donaldson S; Belyanskaya LL; Simões-Wüst AP; Sigrist B; Kurtz S; Zangemeister-Wittke U; Stahel R
Neoplasia; 2006 Jul; 8(7):551-9. PubMed ID: 16867217
[TBL] [Abstract][Full Text] [Related]
24. Human tumor suppressor ARF impedes S-phase progression independent of p53.
Yarbrough WG; Bessho M; Zanation A; Bisi JE; Xiong Y
Cancer Res; 2002 Feb; 62(4):1171-7. PubMed ID: 11861400
[TBL] [Abstract][Full Text] [Related]
25. Mutations leading to antifolate resistance in Chinese hamster ovary cells after exposure to the alkylating agent ethylmethanesulfonate.
Fanin R; Banerjee D; Volkenandt M; Waltham M; Li WW; Dicker AP; Schweitzer BI; Bertino JR
Mol Pharmacol; 1993 Jul; 44(1):13-21. PubMed ID: 8341268
[TBL] [Abstract][Full Text] [Related]
26. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
[TBL] [Abstract][Full Text] [Related]
27. Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma.
Kanellou P; Zaravinos A; Zioga M; Spandidos DA
Br J Dermatol; 2009 Jun; 160(6):1215-21. PubMed ID: 19298278
[TBL] [Abstract][Full Text] [Related]
28. Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control.
Hasan MK; Yaguchi T; Minoda Y; Hirano T; Taira K; Wadhwa R; Kaul SC
Biochem J; 2004 Jun; 380(Pt 3):605-10. PubMed ID: 15109303
[TBL] [Abstract][Full Text] [Related]
29. p14Arf acts as an antagonist of HMGA2 in senescence of mesenchymal stem cells-implications for benign tumorigenesis.
Markowski DN; Winter N; Meyer F; von Ahsen I; Wenk H; Nolte I; Bullerdiek J
Genes Chromosomes Cancer; 2011 Jul; 50(7):489-98. PubMed ID: 21456046
[TBL] [Abstract][Full Text] [Related]
30. Cancer research: from folate antagonism to molecular targets.
Bertino JR
Best Pract Res Clin Haematol; 2009 Dec; 22(4):577-82. PubMed ID: 19959110
[TBL] [Abstract][Full Text] [Related]
31. Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells.
Rhee MS; Balinska M; Bunni M; Priest DG; Maley GF; Maley F; Galivan J
Cancer Res; 1990 Jul; 50(13):3979-84. PubMed ID: 2162250
[TBL] [Abstract][Full Text] [Related]
32. The co-transfection of p16(INK4a) and p14(ARF) genes into human lung cancer cell line A549 and the effects on cell growth and chemosensitivity.
Xie QC; Hu YD; Wang LL; Chen ZT; Diao XW; Wang ZX; Guan HJ; Zhu B; Sun JG; Duan YZ; Chen FL; Nian WQ
Colloids Surf B Biointerfaces; 2005 Dec; 46(3):188-96. PubMed ID: 16337111
[TBL] [Abstract][Full Text] [Related]
33. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Marverti G; Ligabue A; Paglietti G; Corona P; Piras S; Vitale G; Guerrieri D; Luciani R; Costi MP; Frassineti C; Moruzzi MS
Eur J Pharmacol; 2009 Aug; 615(1-3):17-26. PubMed ID: 19446547
[TBL] [Abstract][Full Text] [Related]
34. p53-Dependent and -independent functions of the Arf tumor suppressor.
Sherr CJ; Bertwistle D; DEN Besten W; Kuo ML; Sugimoto M; Tago K; Williams RT; Zindy F; Roussel MF
Cold Spring Harb Symp Quant Biol; 2005; 70():129-37. PubMed ID: 16869746
[TBL] [Abstract][Full Text] [Related]
35. Retroviral coexpression of thymidylate synthase and dihydrofolate reductase confers fluoropyrimidine and antifolate resistance.
Fantz CR; Shaw D; Moore JG; Spencer HT
Biochem Biophys Res Commun; 1998 Feb; 243(1):6-12. PubMed ID: 9473470
[TBL] [Abstract][Full Text] [Related]
36. Design and rationale for novel antifolates.
Bertino JR; Sobrero A; Mini E; Moroson BA; Cashmore A
NCI Monogr; 1987; (5):87-91. PubMed ID: 3431593
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
[TBL] [Abstract][Full Text] [Related]
39. Folate and antifolate pharmacology.
Kamen B
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019
[TBL] [Abstract][Full Text] [Related]
40. Antifolate resistance and its circumvention by new analogues.
Takemura Y; Kobayashi H; Miyachi H
Hum Cell; 2001 Sep; 14(3):185-202. PubMed ID: 11774738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
